MedTrace Logo

Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)

NCT01092091 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-03-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).

Conditions

Interventions

BIOLOGICAL

Pegylated Recombinant Human Arginase I

Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg

Sponsors & Collaborators

  • The University of Hong Kong

    collaborator OTHER

  • Chinese University of Hong Kong

    collaborator OTHER

  • Bio-Cancer Treatment International Limited

    lead INDUSTRY

Principal Investigators

  • Ronnie TP Poon, Prof · Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092091 on ClinicalTrials.gov